Ozempic’s health benefits keep growing, but are the risks worth it?
One in eight adults in the U.S. has taken Ozempic or another type of GLP-1 drug, surveys show — and now a major new study has revealed a long list of benefits and some little-known risks.
Glucagon-like peptide-1 receptor (GLP-1) agonists — which contain either semaglutide or liraglutide — are prescribed to treat type 2 diabetes and obesity, but previous studies have linked the drugs to other, unexpected benefits.
Researchers at Washington University School of Medicine in St. Louis and the Veterans Affairs (VA) St. Louis Health Care System studied the health outcomes of more than two million veterans with diabetes who took Ozempic or another type of GLP-1 drug between Oct. 1, 2017 and Dec. 31, 2023, according to a university press release.
OZEMPIC 'MICRODOSING' IS THE NEW WEIGHT-LOSS TREND
They then compared those outcomes to veterans who took non-GLP-1 diabetes medications.
The study, published in the journal Nature on Jan. 20, identified «widespread associations» between Oze..